Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo

J Control Release. 2012 Mar 10;158(2):207-14. doi: 10.1016/j.jconrel.2011.10.032. Epub 2011 Oct 30.

Abstract

Molecular imaging of angiogenesis requires a highly specific and efficient contrast agent for targeting activated endothelium. We have previously demonstrated that paramagnetic and fluorescent liposomes functionalized with two angiogenesis-specific ligands, the galectin-1-specific anginex (Anx) and the α(v)β(3) integrin-specific RGD, produce synergistic targeting effect in vitro. In the current study, we applied Anx and RGD dual-conjugated liposomes (Anx/RGD-L) for angiogenesis-specific MRI in vivo, focusing on the specificity and efficacy of liposome association with tumor endothelium. The targeting properties, clearance kinetics and biodistribution of Anx/RGD-L were investigated in B16F10 melanoma-bearing mice, and compared to liposomes functionalized with either Anx (Anx-L) or RGD (RGD-L). The contrast enhancement produced by dual- and single-targeted nanoparticles in the tumor was measured using in vivo T(1)-weighted MRI, complemented by ex vivo immunohistochemical evaluation of tumor tissues. Blood clearance kinetics of Anx/RGD-L was three-fold more rapid than for RGD-L, but comparable to Anx-L. Both dual- and single-targeted liposomes produced similar changes in MRI contrast parameters in tumors with high inter-tumor variability (ΔR(1)=0.04±0.03s(-1), 24h post-contrast). Importantly, however, the specificity of Anx/RGD-L association with tumor endothelium of 53±6%, assessed by fluorescence microscopy, was significantly higher compared to 43±9% (P=0.043) and 28±8% (P=0.0001) of Anx-L and RGD-L, respectively. In contrast, long-circulating RGD-L were on average 16% more efficient in targeting tumor endothelium compared to Anx/RGD-L. Significant differences were also found in the biodistribution of investigated contrast agents. In conclusion, synergistic targeting of α(v)β(3) and galectin-1 improved the specificity of the association of the liposomal contrast agent to tumor endothelium in vivo, providing therefore a more reliable MRI readout of the angiogenic activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Contrast Media / administration & dosage*
  • Contrast Media / pharmacokinetics
  • Endothelium, Vascular / metabolism
  • Galectin 1 / metabolism*
  • Integrin alphaVbeta3 / metabolism*
  • Liposomes
  • Magnetics
  • Melanoma, Experimental / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Microscopy, Fluorescence
  • Oligopeptides / administration & dosage*
  • Oligopeptides / pharmacokinetics
  • Peptides / administration & dosage*
  • Peptides / pharmacokinetics

Substances

  • Contrast Media
  • Galectin 1
  • Integrin alphaVbeta3
  • Liposomes
  • Oligopeptides
  • Peptides
  • anginex peptide
  • arginyl-glycyl-aspartic acid